新突变扩展FAT1肾病谱并揭示Hippo信号改变
研究纳入4例FAT1相关肾病患者(3个家系),进行临床遗传学分析并与既往病例对比。患者均表现眼部表型及异质性肾脏表型,尿液上皮细胞显示Hippo通路MST和YAP磷酸化降低、YAP靶基因转录上调。错义突变者表型多样,截短突变者表型较一致。
要点
- FAT1相关肾病可表现为眼部表型合并异质性肾脏病变。
- 截短突变者表型较一致,错义突变者表型高度多样。
- Hippo信号改变和YAP去抑制可能是FAT1肾病新机制。
核心结论
- 新发现的FAT1突变扩展了FAT1相关肾病谱,截短突变者表型更一致,错义突变者表型高度多样。
研究设计与样本
- 研究纳入4例FAT1相关疾病患者(来自3个家系),进行临床和遗传学表征,并与既往发表患者比较。
主要发现
- 4例患者中3例为纯合截短变异,1例为复合杂合错义变异。
- 所有患者均有眼科表型,肾脏表型从肾功能正常到早发终末期肾衰竭不等。
- 患者来源尿液肾上皮细胞显示MST和YAP磷酸化降低,YAP靶基因转录上调。
临床怎么用
- 对疑似FAT1肾病患者应关注眼部表型,并考虑基因检测明确突变类型。
局限性
- 样本量小(4例患者),需更大队列验证基因型-表型关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Disease-causing mutations in the protocadherin FAT1 have been recently described both in patients with a glomerulotubular nephropathy and in patients with a syndromic nephropathy. METHODS: We identified 4 patients with FAT1-associated disease, performed clinical and genetic characterization, and compared our findings to the previously published patients. Patient-derived primary urinary epithelial cells were analyzed by quantitative polymerase chain reaction (qPCR) and immunoblotting to identify possible alterations in Hippo signaling. RESULTS: Here we expand the spectrum of FAT1-associated disease with the identification of novel FAT1 mutations in 4 patients from 3 families (homozygous truncating variants in 3, compound heterozygous missense variants in 1 patient). All patients show an ophthalmologic phenotype together with heterogeneous renal phenotypes ranging from normal renal function to early-onset end-stage kidney failure. Molecular analysis of primary urine-derived urinary renal epithelial cells revealed alterations in the Hippo signaling cascade with a decreased phosphorylation of both the core kinase MST and the downstream effector YAP. Consistently, we found a transcriptional upregulation of bona fide YAP target genes. CONCLUSION: A comprehensive review of the here identified patients and those previously published indicates a highly diverse phenotype in patients with missense mutations but a more uniform and better recognizable phenotype in the patients with truncating mutations. Altered Hippo signaling and de-repressed YAP activity might be novel contributing factors to the pathomechanism in FAT1-associated renal disease.
引用
- Fabretti F, Tschernoster N, Erger F, et al. Expanding the Spectrum of FAT1 Nephropathies by Novel Mutations That Affect Hippo Signaling. Kidney Int Rep. 2021. PMID: 34013115. doi:10.1016/j.ekir.2021.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。